Stories
Sun Pharma Board to Consider 15000 Crore NCD Issue on October 12
- •Sun Pharmaceutical Industries Ltd announced that its board will meet on October 12 to consider issuing non-convertible debentures worth up to 15000 crore rupees.
- •The NCDs will be issued in one or more tranches through private placement.
- •Sun Pharma recently partnered with LIB Therapeutics for the commercialisation and manufacturing of the bad cholesterol treatment drug lerodalcibep.
- •The global licensing agreement strengthens Sun Pharma's innovative medicines portfolio by granting access to the growing PCSK9 market.
Key Questions Answered
The board of Sun Pharmaceutical Industries Ltd will meet on Monday, October 12, 2026, to consider and approve the issuance of listed, rated, unsecured, and redeemable non-convertible debentures (NCDs) worth up to ₹15,000 crore.
Lerodalcibep is a novel antibody-mimetic biologic and recombinant fusion protein that inhibits PCSK9 to lower low-density lipoprotein cholesterol (LDL-C) in adults. It is approved for treating hypercholesterolemia and mixed dyslipidemia under brand names like Lyrokaul in the EU and Lerochol in the US.
Sun Pharma and its subsidiaries entered an exclusive licensing agreement with LIB Therapeutics Inc. to manufacture and commercialize lerodalcibep worldwide, excluding the US and China. LIB Therapeutics will receive upfront and milestone payments, plus royalties on net sales.
